XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$29.25 USD
-0.25 (-0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $29.27 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.25 USD
-0.25 (-0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $29.27 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Zacks News
5 of the Best-Performing Biotech Stocks of 2017
by Arpita Dutt
With 2017 coming to an end, it is time to take a look at the performance of the biotech sector and some of the best-performing biotech stocks including XOMA (XOMA).
4 Biotech Stocks That More Than Doubled This Year
by Zacks Equity Research
We take a look at a few biotech stocks whose price has increased more than 100% in 2017.
3 Buy-Ranked Biotech Stocks That Soared in 2017
by Benjamin Rains
The S&P 500 is up almost 20% in 2017, with the likes of technology giants Nvidia (NVDA) and Amazon (AMZN) helping lift the index to new heights.
Pfizer's Leukemia Drug Gets FDA Nod in First-Line Setting
by Zacks Equity Research
Pfizer's (PFE) leukemia drug Bosulif receives FDA approval in first-line setting.
Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies
by Zacks Equity Research
Biogen (BIIB) expands collaboration with Ionis to identify new drug candidates for the treatment of SMA.
Pfizer Hikes Dividend, Announces $10B Share Buyback Plan
by Zacks Equity Research
Pfizer (PFE) raises quarterly dividend for 2018 while also authorizing a new $10 billion share repurchase program.
Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran
by Zacks Equity Research
Sanofi (SNY) and Alnylam announced that the FDA has lifted the clinical hold placed on all ongoing studies of its hemophilia candidate, fitusiran.
Vertex Kalydeco Study Successful in Children Aged 1-2 Years
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.
4 Biotech Stocks to Better Your Financial Health This Winter
by Zacks Equity Research
The biotech industry shows a solid performance so far this year except for a brief slump in between of late. However, it is a good idea to select stocks from a sector that is fundamentally strong.
XOMA (XOMA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in XOMA Corporation (XOMA).
Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2- advanced or metastatic breast cancer.
Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data
by Arpita Dutt
Major highlights this week were earnings results from companies like Celgene (CELG) and pipeline updates.